UBS Group’s TRANSITION THERAPEUTICS INC (CANADA) TTHI Stock Holding History

UBS Group’s Portfolio TTHI Stock Details TTHI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1,956	Closed	-$3K	–	8430
2016 Q2	$3K	Buy	1,956 +867	+80%	+$752	﹤0.01%	7405
2016 Q1	$1K	Sell	1,089 -459	-30%	-$530	﹤0.01%	7554
2015 Q4	$3K	Sell	1,548 -19	-1%	-$36	﹤0.01%	7972
2015 Q3	$3K	Buy	+1,567	New	+$3.33K	﹤0.01%	8035
2015 Q2	–	Sell	-2,981	Closed	-$20K	–	9372
2015 Q1	$20K	Buy	+2,981	New	+$20.6K	﹤0.01%	7013

Other funds holding TTHI

HCM

Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

UBS Group's TTHI Position: Q3 2016 in Review

UBS Group sold out of TRANSITION THERAPEUTICS INC (CANADA) (TTHI) in Q3 2016, closing a stake of 1,956 shares — an estimated $3K sold.

UBS Group first reported a position in TTHI in Q1 2015 and held it in 5 quarters. The position peaked at $20K in Q1 2015. 2 funds tracked by Wall St. Rank hold TTHI as of Q3 2016.

UBS Group reported no remaining TRANSITION THERAPEUTICS INC (CANADA) position as of Q3 2016 after selling out during the quarter.
UBS Group sold 1,956 TRANSITION THERAPEUTICS INC (CANADA) shares in Q3 2016, an estimated $3K.
UBS Group first reported a position in TRANSITION THERAPEUTICS INC (CANADA) in Q1 2015 and held it in 5 quarters.
UBS Group's TRANSITION THERAPEUTICS INC (CANADA) position peaked at $20K in Q1 2015.
2 funds tracked by Wall St. Rank held TRANSITION THERAPEUTICS INC (CANADA) as of Q3 2016.

Based on UBS Group's 13F filing for Q3 2016, filed 14 Nov 2016.